Nano Drug Delivery Advancement Discloses New Opportunities for the Treatment of Pulmonary Fibrosis
A current advancement publication by researchers at the Masonic Medical Research Institute has discovered a novel way of treating pulmonary fibrosis. This progressive, incurable disease leads to the stiffening of the lungs through scarring, using nanoparticles.
However, nano drug delivery is a promising field that offers significant possibilities for the treatment of pulmonary fibrosis. Pulmonary fibrosis is a progressive and chronic lung disease that causes the lungs to become scarred and stiff, causing difficulty in breathing. The condition has no known treatment, and present treatments only aim to manage symptoms.
Nano drug delivery involves the use of nanoparticles to deliver drugs to certain cells or tissues in the body. This technology offers several advantages over traditional drug delivery techniques, consisting of enhanced drug efficacy, reduced side effects, and the ability to target particular cells or tissues.
” While these researches do not yet mainly treat this illness outright, it reveals we have the potential to substantially impact and boost the quality of life for those affected,” stated the research study’s elderly researcher, Jason R. McCarthy, Ph.D., Associate Teacher and likewise Science Operations Director at MMRI.
Dr. McCarthy and fifteen collaborators on this project, including scientists from the MMRI, Massachusetts General Hospital, and also Harvard Medical School, embarked on this research study in 2015. This year, their findings were posted in the American Journal of Physiology-Lung Cellular and additionally Molecular Physiology.
Therefore, The group focused on the growth of nanoparticles able to target fibroblasts in the lung– the cell responsible for the scarring– to give an efficient medication that halts the problem’s progression.
Dr. McCarthy and his team are recently investigating whether this technique can benefit other cell kinds in the lung, likewise elucidating how they work or break down during idiopathic pulmonary fibrosis. Also, they are broadening their research study research beyond the lung to investigate how this strategy can work for organ systems, involving the heart and liver.
Read the original original article on PHYS.
Read more: Long-term Air Pollution Exposure Associated to Late-Life Depression.
